[CAS NO. 69655-05-6] Didanosine
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [69655-05-6]
Catalog
HY-B0249
Brand
MCE
CAS
69655-05-6
DESCRIPTION [69655-05-6]
Overview
| MDL | MFCD00077728 |
|---|---|
| Molecular Weight | 236.23 |
| Molecular Formula | C10H12N4O3 |
| SMILES | OC[C@@H]1CC[C@H](N2C3=C(N=C2)C(O)=NC=N3)O1 |
For research use only. We do not sell to patients.
1 Publications Citing Use of MCE
Summary
Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV [1] [2] [3] .
In Vitro
Didanosine is converted by cellular enzymes to the active antiviral metabolite dideoxyadenosine triphosphate (dd-ATP) and the intracellular half life of dd-ATP varies from 8-24 hours
[1]
.
Didanosine shows antiretroviral activity with IC
50
value of 0.24-0.6 mg/L for HIV infection
[3]
.
Didanosine (5, 10, 50, 100 ug/ml; 24, 48 h) shows no significant inhibition of cell proliferation in IEC-6 cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | IEC-6 cells |
| Concentration: | 5, 10, 50, 100 ug/ml |
| Incubation Time: | 24, 48 h |
| Result: | Did not show any significant inhibition of cell proliferation at either 24 h or 48 h. |
Apoptosis Analysis [2]
| Cell Line: | IEC-6 cells |
| Concentration: | 100 ug/ml |
| Incubation Time: | 24 h |
| Result: | Induced apoptosis with the apoptosis rates of 4.7% to 7.4%. |
In Vivo
Didanosine (100, 150 mg/kg; p.o.; daily for 7 days) decreases the length of duodenal and in jejunal villus in mouse [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 30-40 g, male swiss mice [2] |
| Dosage: | 100, 150 mg/kg |
| Administration: | P.o.; daily for 7 days |
| Result: | Caused significant reductions in duodenal and in jejunal villus length and significantly decreased ileal crypt depth. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00001024 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Not Applicable | |
| NCT00002001 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00034086 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00051090 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|Hepatitis B
|
Not Applicable | |
| NCT00002224 | Bristol-Myers Squibb |
HIV Infections
|
March 1999 | Phase 3 |
| NCT00001074 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00000671 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00091936 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|Tuberculosis
|
August 2009 | Not Applicable |
| NCT00013520 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 3 | |
| NCT00000814 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00005000 | Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
December 1999 | Phase 4 |
| NCT03581994 | Qure Healthcare, LLC|Aegis Sciences Corporation |
Drug-Drug Interactions
|
May 2, 2018 | Not Applicable |
| NCT00000924 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
HIV Infections
|
Phase 2 | |
| NCT00000657 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
AIDS Dementia Complex|HIV Infections
|
Phase 2 | |
| NCT00002109 | Immunobiology Research Institute|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00000851 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00008489 | PharmaResearch|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00000939 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00002234 | Gilead Sciences|Bristol-Myers Squibb|Glaxo Wellcome|Dupont Applied Biosciences |
HIV Infections
|
Phase 2 | |
| NCT00116415 | Bristol-Myers Squibb |
HIV Infections|AIDS
|
March 2002 | Not Applicable |
| NCT00001087 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00001122 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000982 | National Institute of Allergy and Infectious Diseases (NIAID)|National Cancer Institute (NCI) |
Encephalopathies|HIV Infections
|
Phase 2 | |
| NCT00002176 | Bristol-Myers Squibb |
HIV Infections
|
May 1997 | Not Applicable |
| NCT00002240 | Bristol-Myers Squibb |
HIV Infections
|
March 1999 | Phase 2 |
| NCT00928187 | ANRS, Emerging Infectious Diseases|Gilead Sciences|Janssen Pharmaceutica |
HIV|HIV Infections
|
November 2009 | Phase 3 |
| NCT00002376 | Merck Sharp & Dohme LLC|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 4 | |
| NCT00000885 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00080522 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
February 2005 | Not Applicable |
| NCT00001108 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
HIV Infections
|
Phase 1 | |
| NCT00002211 | Pharmacia and Upjohn|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00006339 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000954 | National Institute of Allergy and Infectious Diseases (NIAID)|Novum|Bristol-Myers Squibb |
Sarcoma, Kaposi|HIV Infections
|
Phase 1 | |
| NCT00006154 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 3 | |
| NCT00342355 | National Institutes of Health Clinical Center (CC) |
HIV
|
January 2004 | Phase 4 |
| NCT00000781 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00008866 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00005018 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
July 1999 | Phase 4 |
| NCT00001022 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 3 | |
| NCT00002386 | Merck Sharp & Dohme LLC|NIH AIDS Clinical Trials Information Service |
HIV Infections|Hemophilia A
|
Phase 4 | |
| NCT00002177 | Bristol-Myers Squibb |
HIV Infections
|
May 1997 | Not Applicable |
| NCT00000669 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 1 | |
| NCT00000891 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00002313 | Argus Pharmaceuticals|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 1 | |
| NCT00001114 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough|Bristol-Myers Squibb |
Sarcoma, Kaposi|HIV Infections
|
Phase 2 | |
| NCT00000823 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00002230 | Northwestern University|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00000742 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn|Glaxo Wellcome |
HIV Infections
|
Phase 1 | |
| NCT00007202 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00001048 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Upjohn |
HIV Infections|Leukoencephalopathy, Progressive Multifocal
|
Phase 2 | |
| NCT00000902 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00001267 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
AIDS-Related Complex|Acquired Immunodeficiency Syndrome
|
October 1990 | Phase 3 |
| NCT00192660 | Kirby Institute|St Vincent´s Hospital, Sydney|National Heart, Lung, and Blood Institute (NHLBI) |
HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease
|
February 2003 | Phase 4 |
| NCT00001035 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough |
HIV Infections|Hepatitis C
|
Phase 1 | |
| NCT00002207 | Bristol-Myers Squibb |
HIV Infections
|
February 2004 | Not Applicable |
| NCT00042289 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
HIV Infections
|
June 9, 2003 | |
| NCT00000625 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00002028 | Bristol-Myers Squibb |
HIV Infections
|
Not Applicable | |
| NCT00000865 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00002014 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 1 | |
| NCT00001049 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00006208 | Triangle Pharmaceuticals|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
August 2000 | Phase 3 |
| NCT00000831 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000810 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00084136 | AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
May 2005 | Phase 4 |
| NCT00000916 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000833 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00142337 | Institut de Recherche pour le Developpement |
HIV Infections
|
December 2004 | Phase 2 |
| NCT00000760 | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche |
HIV Infections
|
Phase 1 | |
| NCT00002427 | Research Institute for Genetic and Human Therapy|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
May 1999 | Phase 1 |
| NCT00256828 | Clinical Trial Agency of HIV Study Group |
HIV Infections
|
June 2004 | Phase 4 |
| NCT00000652 | National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00002225 | Dupont Merck|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00001066 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00000637 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 3 | |
| NCT00000922 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00002418 | Bristol-Myers Squibb|Boehringer Ingelheim|Triangle Pharmaceuticals |
HIV Infections
|
Phase 2 | |
| NCT00000656 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 1 | |
| NCT00002411 | Bristol-Myers Squibb |
HIV Infections
|
March 1998 | Not Applicable |
| NCT00000753 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn|Glaxo Wellcome |
HIV Infections
|
Phase 1 | |
| NCT00002407 | Weill Medical College of Cornell University|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00002123 | Pharmacia and Upjohn|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 3 | |
| NCT00001997 | Chiron Corporation|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Not Applicable | |
| NCT00002168 | Bristol-Myers Squibb |
HIV Infections
|
Not Applicable | |
| NCT00000919 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00001057 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000918 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000969 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Hoffmann-La Roche |
HIV Infections
|
Not Applicable | |
| NCT00000803 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00001025 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00002098 | AJI Pharma USA|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 1 | |
| NCT00014937 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00102960 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
July 2005 | Phase 3 |
| NCT00074581 | National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network |
HIV Infections
|
February 2005 | Phase 3 |
| NCT00002035 | Bristol-Myers Squibb |
HIV Infections
|
Not Applicable | |
| NCT00002420 | Bristol-Myers Squibb|Pharmacia and Upjohn|Triangle Pharmaceuticals |
HIV Infections
|
Phase 2 | |
| NCT00000979 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00002412 | Triangle Pharmaceuticals|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00001029 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00000839 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections|Pregnancy
|
Phase 1 | |
| NCT00338390 | Hospital de Granollers |
HIV Infections
|
April 2005 | Phase 3 |
| NCT00002274 | Bristol-Myers Squibb |
HIV Infections|Leukoencephalopathy, Progressive Multifocal
|
Not Applicable | |
| NCT00000870 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000838 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 2 | |
| NCT00000963 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00002280 | Bristol-Myers Squibb |
HIV Infections
|
Not Applicable | |
| NCT00000770 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00000672 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00002429 | Bristol-Myers Squibb |
HIV Infections
|
July 1999 | Phase 3 |
| NCT00002162 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00006397 | PPD|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
August 2000 | Phase 3 |
| NCT00002905 | Centro di Riferimento Oncologico - Aviano|National Cancer Institute (NCI) |
Lymphoma
|
June 1995 | Phase 2 |
| NCT00001063 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb |
HIV Infections
|
Phase 2 | |
| NCT00000923 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Not Applicable | |
| NCT00002099 | AJI Pharma USA|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
| NCT00122538 | French National Agency for Research on AIDS and Viral Hepatitis |
HIV Infections|AIDS
|
February 2006 | Phase 2 |
| NCT00000710 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00002096 | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Infections|HIV Infections
|
Phase 1 | |
| NCT00668356 | Assistance Publique - Hôpitaux de Paris |
HIV Infections
|
September 2009 | Phase 2 |
| NCT00158470 | French National Agency for Research on AIDS and Viral Hepatitis |
HIV Infection
|
September 2003 | Phase 3 |
| NCT00000971 | Abbott|National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID) |
Mycobacterium Avium-intracellulare Infection|HIV Infections
|
Phase 1 | |
| NCT00000772 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|ICN Pharmaceuticals |
HIV Infections
|
Phase 1 | |
| NCT00002360 | Bristol-Myers Squibb |
HIV Infections
|
March 1999 | Phase 1 |
| NCT00000822 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Immuno-US |
HIV Infections
|
Phase 1 | |
| NCT00001045 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Glaxo Wellcome |
HIV Infections
|
Phase 2 | |
| NCT00016718 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
HIV Infections
|
August 2001 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 62.5 mg/mL ( 264.57 mM ; Need ultrasonic)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2332 mL | 21.1658 mL | 42.3316 mL |
| 5 mM | 0.8466 mL | 4.2332 mL | 8.4663 mL |
| 10 mM | 0.4233 mL | 2.1166 mL | 4.2332 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
*
All of the co-solvents are available by MCE.
References
- [1] Munir N.Nassar, et al. Analytical profiles of drug substances and excipients. Journals & Books, 1993, 185-227.
- [2] Braga Neto MB, et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol. 2010 Aug 11;10:90.
- [3] Caroline M. Perry, et al. Didanosine. Drugs, 1999, 58, 1099-1135.
Synonyms
Inosine, 2′,3′-dideoxy-
2′,3′-Dideoxyinosine
NSC 612049
Didanosine
BMY 40900
DdI
Videx
Dideoxyinosine
DdI (nucleoside)
Videx EC
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.